Physician profile
James Collier
NPI 1841265816
$1,616.39
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $971 · 2020: $609 · 2022: $36.72.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $281.43 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $243.93 | 2019-2020 | |
| Akebia Therapeutics INC | $208.62 | 2019 | |
| Astellas Pharma US INC | $151.69 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $119.77 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $117.91 | 2019-2020 | |
| Amarin Pharma, INC. | $84.55 | 2019-2020 | |
| Lilly USA, LLC | $82.35 | 2019 | |
| Janssen Pharmaceuticals, INC | $76.68 | 2019 | |
| Alexion Pharmaceuticals, INC. | $50.19 | 2019-2020 | |
| Pfizer INC. | $47.08 | 2019 | |
| Novo Nordisk INC | $31.25 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.05 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $23.30 | 2020 | |
| Abbott Laboratories | $19.17 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $17.84 | 2020 | |
| Vifor Pharma, INC. | $17.55 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $17.03 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Collier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.